Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 4, 2011, Pages 1081-1087

  Eroglu, Zeynep ^a   Kong, Kevin M ^a   Jakowatz, James G ^a   Samlowski, Wolfram ^b   Fruehauf, John P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEVADA CANCER INSTITUTE   (United States)

Author keywords

Docetaxel; Melanoma; Phase II; Sargramostim; Vinorelbine

Indexed keywords

DOCETAXEL; INTERFERON; INTERLEUKIN 2; NAVELBINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BONE PAIN; BRAIN METASTASIS; CANCER PATIENT; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CHILL; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG FEVER; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL RATE; TASTE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 80054760671     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1703-z     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. Cancer J Clin 59:225-249
2. S Markovich L Erickson R Rao 2007 Malignant melanoma in the 21st century, Part 2: staging, prognosis, and treatment Mayo Clin Proc 82 490 513 10.4065/82.4.490 (Pubitemid 46543475)
3. MR Middleton JJ Grob N Aaronson G Fierlbeck W Tilgen S Seiter M Gore S Aamdal J Cebon A Coates B Dreno M Henz D Schadendorf A Kapp J Weiss U Fraass P Statkevich M Muller N Thatcher 2000 Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 158 166 10623706 1:CAS:528: DC%2BD3cXmtFSqsQ%3D%3D (Pubitemid 30036349)
4. MB Atkins MT Lotze JP Dutcher RI Fisher G Weiss K Margolin J Abrams M Sznol D Parkinson M Hawkins C Paradise L Kunkel SA Rosenberg 1999 High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 2105 2116 10561265 1:CAS:528:DyaK1MXkvVSmur4%3D (Pubitemid 29318842)
5. FO Smith SG Downey JA Klapper JC Yang RM Sherry RE Royal US Kammula MS Hughes NP Restifo CL Levy DE White SM Steinberg SA Rosenberg 2008 Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines Clin Cancer Res 14 5610 5618 18765555 10.1158/1078-0432.CCR-08-0116 1:CAS:528:DC%2BD1cXhtVKmtr7O
6. MB Atkins J Hsu S Lee GI Cohen LE Flaherty JA Sosman VK Sondak JM Kirkwood 2008 Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the eastern cooperative oncology group J Clin Oncol 2 5748 5754 10.1200/JCO.2008.17.5448
7. O Eton SS Legha AY Bedikian JJ Lee AC Buzaid C Hodges SE Ring NE Papadopoulos C Plager MJ East F Zhan RS Benjamin 2002 Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial J Clin Oncol 20 2045 2052 11956264 10.1200/JCO.2002.07.044 1:CAS:528:DC%2BD38XjvVKmsrg%3D (Pubitemid 34408794)
8. NJ Ives RL Stowe P Lorigan K Wheatley 2007 Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2, 621 patients J Clin Oncol 25 5426 5434 18048825 10.1200/JCO.2007.12.0253 1:CAS:528:DC%2BD1cXnvVCitw%3D%3D (Pubitemid 350232219)
9. FS Hodi SJ O'Day DF McDermott RW Weber JA Sosman JB Haanen R Gonzalez C Robert D Schadendorf JC Hassel W Akerley AJ van den Eertwegh J Lutzky P Lorigan JM Vaubel GP Linette D Hogg CH Ottensmeier C Lebbé C Peschel I Quirt JI Clark JD Wolchok JS Weber J Tian MJ Yellin GM Nichol A Hoos WJ Urba 2010 Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 711 723 20525992 10.1056/NEJMoa1003466 1:CAS:528:DC%2BC3cXhtVCrtrbN
10. KT Flaherty I Puzanov KB Kim A Ribas GA McArthur JA Sosman PJ O'Dwyer RJ Lee JF Grippo K Nolop PB Chapman 2010 Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 809 819 20818844 10.1056/NEJMoa1002011 1:CAS:528:DC%2BC3cXhtVyksb3M
11. R Nazarian H Shi Q Wang X Kong RC Koya H Lee Z Chen MK Lee N Attar H Sazegar T Chodon SF Nelson G McArthur JA Sosman A Ribas RS Lo 2010 Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 973 977 21107323 10.1038/nature09626 1:CAS:528:DC%2BC3cXhsVOrsbjI
12. A Photiou P Shah LK Leong J Moss S Retsas 1997 In vitro synergy of paclitaxel (Taxol) and vinorelbine (Navelbine) against human melanoma cell lines Eur J Cancer 33 463 470 9155533 10.1016/S0959-8049(97)89023-5 1:CAS:528:DyaK2sXislagurc%3D (Pubitemid 27168075)
13. MH Neale NE Myatt GG Khoury P Weaver A Lamont JL Hungerford CM Kurbacher P Hall PG Corrie IA Cree 2001 Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma Melanoma Res 11 601 609 11725206 10.1097/00008390-200112000-00006 1:CAS:528:DC%2BD38XisFWktg%3D%3D (Pubitemid 33152351)
14. Wu H, Xin Y, Zhao J, Sun D, Li W, Hu Y, Wang S (2011) Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model. Cancer Chemother Pharmacol Feb 3. [Epub ahead of print]
15. JM Sanchez C Balana A Font JJ Sánchez JL Manzano M Guillot M Margelí M Richardet R Rosell 2002 Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer Lung Cancer 38 309 315 12445754 10.1016/S0169- 5002(02)00220-9 (Pubitemid 35341807)
16. J Rodriguez E Calvo J Cortes M Santisteban J Perez-Calvo R Martínez-Monge A Brugarolas O Fernandez-Hidalgo 2002 Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study Breast Cancer Res Treat 76 47 56 12408375 10.1023/A:1020273502426 1:CAS:528:DC%2BD38XntVKjtbc%3D (Pubitemid 35189609)
17. A Gomez-Bernal JJ Cruz A Garcia-Palomo A Arizcun E Pujol P Diz G Martín E Fonseca P Sánchez C Rodríguez E del Barco Y López 2003 Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study Am J Clin Oncol 26 127 131 12714881 10.1097/00000421-200304000-00005 1:CAS:528:DC%2BD3sXntV2jt7o%3D (Pubitemid 36443552)
18. S Retsas A Mohith H Mackenzie 1996 Taxol and vinorelbine: a new active combination for disseminated malignant melanoma Anticancer Drugs 7 161 165 8740720 10.1097/00001813-199602000-00003 1:CAS:528:DyaK28XjtF2ksbo%3D (Pubitemid 26150557)
19. A Jimeno R Hitt M Quintela-Fandino 2005 Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma Anticancer Drugs 16 53 57 15613904 10.1097/00001813-200501000-00007 1:CAS:528:DC%2BD2cXhtFSnsbzL
20. RP Whitehead J Moon SS McCachren EM Hersh WE Samlowski JT Beck NS Tchekmedyian VK Sondak 2004 A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a southwest oncology group study Cancer 100 1699 1704 15073859 10.1002/cncr.20183 1:CAS:528:DC%2BD2cXjvFygtLs%3D (Pubitemid 38456348)
21. LG Feun N Savaraj J Hurley A Marini S Lai 2000 A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma Cancer 88 584 588 10649251 10.1002/(SICI)1097- 0142(20000201)88:3<584::AID-CNCR14>3.0.CO;2-# 1:CAS:528: DC%2BD3cXptVarsQ%3D%3D (Pubitemid 30056933)
22. IJ Fidler ES Kleinerman 1984 Lymphokineactivated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions J Clin Oncol 2 937 943 6379124 1:CAS:528:DyaL2cXlsV2msLs%3D (Pubitemid 14037773)
23. KH Grabstein DL Urdal RJ Tushinski DY Mochizuki VL Price MA Cantrell S Gillis PJ Conlon 1986 Induction of macrophage tumoricidal activity by granulocyte-macrophage colonystimulating factor Science 232 506 508 3083507 10.1126/science.3083507 1:CAS:528:DyaL28Xit1ehsLg%3D (Pubitemid 16052365)
24. MJ Thomassen BP Barna D Rankin HP Wiedemann M Ahmad 1989 Differential effect of recombinant granulocyte macrophage colony-stimulating factor on human monocytes and alveolar macrophages Cancer Res 49 4086 4089 2545332 1:CAS:528:DyaL1MXkvFGhtb4%3D (Pubitemid 19207239)
25. EJ Wing DM Magee TL Whiteside SS Kaplan RK Shadduck 1989 Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients Blood 73 643 646 2465038 1:STN:280:DyaL1M7jsV2rtQ%3D%3D (Pubitemid 19069162)
26. A Chachoua R Oratz R Hoogmoed D Caron D Peace L Liebes RH Blum J Vilcek 1994 Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor J Immunother 15 217 224 10.1097/00002371-199404000-00008 1:STN:280:DyaK2czgsFOgsA%3D%3D (Pubitemid 24100998)
27. R Kumar Z Dong IJ Fidler 1996 Differential regulation of metalloelastase activity in murine peritoneal macrophages by granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor J Immunol 157 5104 5111 8943420 1:CAS:528:DyaK28Xnt1Gqsbg%3D (Pubitemid 126449592)
28. Z Dong R Kumar X Yang IJ Fidler 1997 Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma Cell 88 801 810 9118223 10.1016/S0092-8674(00)81926-1 1:CAS:528:DyaK2sXitFyqsbw%3D (Pubitemid 27164268)
29. G Dranoff E Jaffee A Lazenby P Golumbek H Levitsky K Brose V Jackson H Hamada D Pardoll RC Mulligan 1993 Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci USA 90 3539 3543 8097319 10.1073/pnas.90.8.3539 1:CAS:528: DyaK3sXktVKqt78%3D (Pubitemid 23111402)
30. CA Armstrong R Botella TH Galloway N Murray JM Kramp IS Song JC Ansel 1996 Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells Cancer Res 56 2191 2198 8616871 1:CAS:528:DyaK28Xis1ektbc%3D (Pubitemid 26119924)
31. LE Spitler ML Grossbard MS Ernstoff G Silver M Jacobs FA Hayes SJ Soong 2000 Adjuvant therapy of stage III and IV melanoma using granulocyte-macrophage colony stimulating factor J Clin Oncol 18 1614 1621 10764421 1:CAS:528:DC%2BD3cXjtFajsLw%3D (Pubitemid 30220539)
32. Lawson DH, Lee SJ, Tarhini AA, Margolin KA, Ernstoff MS, Kirkwood JM (2010) E4697: phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. J Clin Oncol 28:15s, (suppl; abstr 8504)
33. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumors: Revised RECIST guideline (Version 1.1). Eur J Cancer 45:228-247
34. R Brookmeyer J Crowley 1982 A confidence interval for the median survival time Biometrics 38 29 41 10.2307/2530286
35. EL Korn PY Liu SJ Lee JA Chapman D Niedzwiecki VJ Suman J Moon VK Sondak MB Atkins EA Eisenhauer W Parulekar SN Markovic S Saxman JM Kirkwood 2008 Meta-analysis of phase ii cooperative group trials in metastatic stage IV melanoma to determine progression free and overall survival benchmarks for future phase II trials J Clin Oncol 26 527 534 18235113 10.1200/JCO.2007.12.7837 (Pubitemid 351264344)
36. -(2010) Melanoma of the Skin. In: AJCC Cancer Staging Manual. Springer, New York, p 325